EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts and advancing the science of tissue transplantation, today announced two of its aseptically processed allografts, AmnioBand® Membrane, an allograft placental matrix, and AlloPatch® Pliable, an allograft dermis matrix, are among the select few tissues to remain covered under the new Medicare medical coverage guidelines. These new guidelines are based on published clinical evidence and reduced the number of covered tissues from over 200 to 17, reaffirming MTF Biologics’ commitment to providing clinically proven solutions for wound care.
Under the new Medicare guidelines, AmnioBand® Membrane and AlloPatch® Pliable are both covered for the treatment of diabetic foot ulcers, offering providers a choice between a placental and dermal allograft solution. AmnioBand® Membrane will be one of only five tissues covered for the treatment of venous leg ulcers. These new guidelines align with the medical coverage policies of the majority of commercial health plans, ensuring broad market applicability for both new and existing distribution partners. They also guarantee that healthcare providers and the Medicare beneficiaries that they treat, who suffer from these recalcitrant wounds, continue to have access to these safe, effective, and economically advantageous tissue forms.
“Medicare’s new guidelines reflect the importance of clinical evidence and quality in wound care solutions,” said Joe Yaccarino, President & Chief Executive Officer of MTF Biologics. “Our inclusion on this exclusive list of covered tissues highlights our ability to deliver trusted tissues that meet the needs of clinicians and patients alike. We are excited to continue to support our distribution partners in delivering a broad range of exceptional, clinically proven solutions to the wound care market.”
MTF Biologics AmnioBand® Membrane and AlloPatch® Pliable key features include:
- Aseptically Processed: Utilizes aseptic processing methods, rather than terminal irradiation, to preserve tissue integrity and quality.
- Dual-Tissue Offering: The only organization on the Medicare list to provide both an allograft dermis matrix (AlloPatch® Pliable) and an allograft placental matrix (AmnioBand® Membrane).
- Proven Clinical Results: Peer-reviewed Level 1 clinical evidence shows these tissues nearly double healing rates compared to standard of care, achieving closure with an average of four applications.
- Cost-Effectiveness: Published studies demonstrate that these high-quality tissues offer some of the lowest cost-to-closure rates and superior outcomes.1,2,3
About MTF Biologics
MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. It provides unmatched service, resources and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers and clinicians and scientists.
The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe.
For more information about our wound care portfolio, visit www.mtfbiologics.org.
- Plast Reconstr Surg Glob Open. 2016 Oct 12:4(10):e1095. eCollection 2016.
- Int Wound J. 2016 Apr 12 doi: 10.1111/iwj.12600 [Epub ahead of print]
- MTF data on file
